Neuroscience Biotech Alkermes Sees Narcolepsy R&D as Launchpad for a Range of New Fatigue Therapies

Alkermes is chasing Takeda Pharmaceutical, whose orexin receptor-targeting pill is on track to become first in a new class of narcolepsy medicines. Blair Jackson, chief operating officer of the neuroscience biotech, says Alkermes’s drug offers advantages and also paves the way to bring orexin agonism to other indications. The post Neuroscience Biotech Alkermes Sees Narcolepsy…

Read More

Dems See Opportunities in Republican Embrace of MAHA Movement

There’s a lot going on in Washington right now. While President Donald Trump has been grabbing for Greenland, he’s also talked in the White House about health policy — whether it’s the Rural Health Transformation Program, ways to address the nation’s spiraling health costs, or an effort to promote whole milk in schools.  At the same time, congressional Republicans are eyeing health issues from the “Make America Healthy Again” perspective, hoping it will provide a boost in the midterm elections.  Here’s why. …

Read More

Healthcare’s Paper Check Problem

By adopting a modern digital payment solution, payers can streamline operations, improve provider relationships and reduce fraud exposure. Most importantly, they gain a flexible, scalable foundation built to meet today’s demands and tomorrow’s challenges. The post Healthcare’s Paper Check Problem appeared first on MedCity News.

Read More

Medicaid: What to Watch in 2026

In this brief on Medicaid issues to watch for 2026, KFF explores how state fiscal pressures are likely to converge with the implementation of the 2025 reconciliation law to affect Medicaid coverage, financing, and access to care over the next year, especially leading up to the midterm elections.

Read More